4295-55-0

Basic information

• Product Name: CLOFENAMIC ACID
• Synonyms: N-2,3-dichlorophenylanthranilic acid;Chlofenamic acid;Clofenamic;ACIDUMCLOFENAMIC;CLOFENAMIC ACID (BP) [N-(2,3-DICHLOROPHENYL)ANTHRANILIC ACID];2-(2,3-Dichloroanilino)benzoic acid;2-[(2,3-Dichlorophenyl)amino]benzoic acid
• CAS NO: 4295-55-0
• Molecular Formula: C₁₃H₉Cl₂NO₂
• Molecular Weight: 282.12
• EINECS: 224-301-3
• Mol File: 4295-55-0.mol
• Article Data: 5

Chemical Properties

• Melting Point: 256-257 °C
• Boiling Point: 407.1 °C at 760 mmHg
• Flash Point: 200 °C
• Appearance: /
• Density: 1.47 g/cm³
• Vapor Pressure: 2.33E-07mmHg at 25°C
• Refractive Index: 1.677
• PKA: 3.61±0.36(Predicted)
• CAS DataBase Reference: CLOFENAMIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: CLOFENAMIC ACID(4295-55-0)
• EPA Substance Registry System: CLOFENAMIC ACID(4295-55-0)

Safety Data

• Hazardous Substances Data: 4295-55-0(Hazardous Substances Data)

Usage

General Description

Clofenamic acid is a non-steroidal anti-inflammatory drug (NSAID) that is used to relieve pain and inflammation in conditions such as arthritis and post-operative pain. It works by inhibiting the production of prostaglandins, which are substances in the body that cause pain and inflammation. Clofenamic acid is known for its strong analgesic and anti-inflammatory properties, and is commonly used in veterinary medicine for the treatment of pain and inflammation in animals. However,

InChI:InChI=1/C13H9Cl2NO2/c14-9-5-3-7-11(12(9)15)16-10-6-2-1-4-8(10)13(17)18/h1-7,16H,(H,17,18)

Upstream product

• 608-27-5 2,3-dichloroaniline 
• 118-91-2 ortho-chlorobenzoic acid 
• 16497-87-3 potassium o-bromobenzoate 
• 88-65-3 2-bromobenzoic-acid 
• 17264-73-2 sodium o-bromobenzoate 
• 88-67-5 2-Iodobenzoic acid 

Downstream Products

• 105837-54-5 2,3-Dichlor-diphenylamin 
• 13581-01-6 N-(2,3-Dichlorphenyl)-anthranilsaeureamid 
• 13581-02-7 N-(2,3-Dichlorphenyl)-anthranilsaeurenitril 

Relevant articles and documents

2-arylamine compound and preparation method and application thereof

The invention discloses a 2-arylamine compound and a preparation method and application thereof. The structure of the 2-arylamine compound is as shown in a formula I shown in the specification, wherein in the formula, the definition of each substituent group is as described in the specification and claims. The compound provided by the invention has a good inhibition effect on fatty acid binding protein 4, and can be used for prevention, treatment or adjuvant treatment of metabolic diseases, inflammations and cancers related to activity or expression of FABP4.

The triphenyltin(VI) complexes of NSAIDs and derivatives. Synthesis, crystal structure and antiproliferative activity. Potent anticancer agents

The novel triphenyltin(IV) esters of flufenamic acid (1), Hflu, [Ph 3Sn(flu)] (2), and of [2-(2,3-dichlorophenylamino)benzoic acid] (3), Hdcpa, [Ph3Sn(dcpa)] (4) have been structurally characterized by means of vibrational and 1H, 13C NMR spectroscopic studies. The crystal and molecular structures of [SnPh3(dcpa)(DMSO)] 4a are described. The molecular structure of 4a reveals that the Sn atom has a distorted trigonal bipyramidal coordination geometry with equatorial phenyl groups and the carboxylate and dimethylsulfoxide oxygen atoms occupying axial positions. The crystal structure of 4a is self-assembled by C-H - -π and π-π stacking interactions. The in vitro cytotoxic activity of 1-4 and of the related non-steroidal anti-inflammatory drugs, NSAIDs, [2-(2,6- dimethylphenylamino)benzoic acid], Hdmpa (5), [Ph3Sn(dmpa)] (6), [2-(2,3-dimethylphenylamino)benzoic acid], mefenamic acid, Hmef (7) and [Ph 3Sn(mef)] (8) has been evaluated against the cancer cell lines MCF-7, T-24, A-549 and L-929. The ligands exhibited very poor cytotoxic activity against the four cancer cell lines. Complex 6 exhibits the highest activity and selectivity against A-549 and MCF-7 cancer cell lines and complex 8 the highest activity and selectivity against T-24 cancer cell line. The cytotoxic results indicate that coupling of Hdmpa and Hmef with R3Sn(IV) metal center results in complexes with important biological properties and remarkable cytotoxic activity, since they display IC50 values in a μΜ range better to that of the antitumor drug cis-platin. Complexes 6 and 8 are considered as excellent antitumor compounds and the results of this study represent the discovery of triphenyltin(IV)esters as a potential novel class of anticancer agents.

Structure-activity relationships in a series of anti-inflammatory N-arylanthranilic acids

A large series of N-arylanthranilic acids has been prepared. Many of these compounds show high anti-inflammatory activity as measured by the anti-UV-erythema test. From this series have come the clinically useful nonsteroidal anti-inflammatory agents, flufenamic acid (Arlef), mefenamic acid (Ponstel), and the latest and most potent agent, N-(2,6-dichloro-m-tolyl)anthranilic acid (meclofenamic acid, Meclomen = the sodium salt). The structure-activity relationships of this series is discussed and a graphical representation is presented which allows the prediction of activity of new agents.